Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 5,830	$ 1,026	$ 8,099	$ 3,135
General and administrative	1,567	509	2,817	1,197
Total operating expenses	7,397	1,535	10,916	4,332
Loss from operations	(7,397)	(1,535)	(10,916)	(4,332)
Other income (expense), net	(1,059)	5	(1,337)	145
Net loss	(8,456)	(1,530)	(12,253)	(4,187)
Unrealized (loss)/gain on available-for-sale securities	7		7
Comprehensive loss attributable to common shareholders	$ (8,449)	$ (1,530)	$ (12,246)	$ (4,187)
Net loss per share attributable to common stockholders, basic and diluted	$ (1.12)	$ (0.43)	$ (2.38)	$ (1.18)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	7,564,538	3,554,345	5,155,338	3,551,586